Oncogenic HER2Δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors

Tamoxifen is the most commonly prescribed therapy for patients with estrogen receptor (ER)α-positive breast tumors. Tumor resistance to tamoxifen remains a serious clinical problem especially in patients with tumors that also overexpress human epidermal growth factor receptor 2 (HER2). Current precl...

Descripción completa

Detalles Bibliográficos
Autores principales: Cittelly, Diana M., Das, Partha M., Salvo, Virgilio A., Fonseca, Juan P., Burow, Matthew E., Jones, Frank E.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994280/
https://www.ncbi.nlm.nih.gov/pubmed/20876285
http://dx.doi.org/10.1093/carcin/bgq192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994280/
https://www.ncbi.nlm.nih.gov/pubmed/20876285
http://dx.doi.org/10.1093/carcin/bgq192

Ejemplares similares